HIV Sample Clauses

HIV. The parties understand that HIV is a highly communicable disease that could be life threatening if proper safety procedures are not followed. Facilities and officers will have available to them, at no cost, high quality HIV germicidal available for immediate use.
Sample 1Sample 2Sample 3See All (5)
AutoNDA by SimpleDocs
HIV. AIDS and combating pandemics The company agrees to apply the principles of the "ILO code of practice on HIV/AIDS and the world of work" and implement employee information campaigns on this epidemic (and any other local pandemic) in at-risk countries: - To put in place awareness and education programmes aimed at employees in their workplace concerning prevention and handling of the sick, notably those with HIV/AIDS - To eliminate all discrimination, particularly in the hiring process, and stigmatisation with regard to the sick - To protect the rights of employees affected (respect for private life and confidentiality, rights and access to services and upholding of the employee relationship) - To provide employees with all the information, help and advice available (support with voluntary and confidential screening, guidance towards specialist internal or external advice and services, aid programmes, etc.) Information actions also apply to service providers and/or subcontractors working on the premises or sites of the company and may also apply to the families of employees when sickness has a major impact on the family. The Group commits its service providers and/or subcontractors to carry out information actions with their employees.
Sample 1Sample 2
HIV. The Parties acknowledge that all milestones payments to JT required under the Original Agreement have been paid and no further amounts are due. Any such payments were and shall be [*] under this Agreement.
Sample 1Sample 2
HIV. IF unable to obtain HIV status or patient is known HIV positive status, drugs for prevention need to be started within 3 hours.
Sample 1Sample 2
HIV. Since HIV transmission most often occurs at the vaginal and rectal mucosa, studies focusing on the role of the microbiota at theses surfaces have become of wide interest and are discussed below. Lactic acid-producing bacteria primarily dominate the vaginal mucosa, and microbiota composition at this surface is less diverse than in the gut. Lowered diversity, however, is associated with greater female reproductive tract health (114). Unlike gut microbiota, very few studies have examined how vaginal microbiota influences immunity at the vagina. Exposure of the vagina to lactic acid-producing bacteria strains was found to decrease inflammation at the lower vaginal epithelium (115, 116). Reducing inflammation would likely decrease the numbers and migration of the primary targets of HIV, including macrophages, DCs, and CD4 T cells, and thus, lower susceptibility to infection at the vaginal mucosa. Some investigators have proposed that vaginal microbiota may regulate susceptibility to HIV infection by making antipathogen products that could directly inhibit virus viability. Indeed, studies have shown that lactic acid, hydrogen peroxide, and bacteriocins made by lactic acid-producing bacteria may prevent infection at the vaginal mucosa (117-119). Furthermore, vaginal microbiota has been shown to make lectins, a group of carbohydrate-binding proteins, which adheres to the surface of HIV, and as a result, lectins may prevent infection of macrophages and DCs by competitively binding to free HIV (120). Microbiota along the gastrointestinal tract has been studied after HIV infection; unfortunately little is known about how microbiota influences initial HIV infectivity. After HIV infection, gut microbiota dramatically changes with higher numbers of pathogens present than beneficial microorganisms (121-123). Furthermore, more microbial translocation from the gut to the blood is observed in HIV-infected individuals; this translocation positively correlates and contributes to chronic inflammation and worsening of many infection-related conditions (124).
Sample 1
HIV. The latest HIV data highlight the reality of multiple epidemics in Somalia with generalized features in and there is a concentrated and low level epidemic in South Central.
Sample 1
HIV. Gilead shall make the following milestone payments to JT based on achievement of the following regulatory and Commercialization milestone events with respect to HIV for Products in the Gilead Territory as set forth in this Section 8.2. Gilead shall notify JT promptly in writing after first achievement of each of the milestone events listed below, and Gilead shall pay to JT the amounts set forth below. Such report and payment may occur together, at the same time, within [*] days of Gilead’s achievement of the relevant milestone event for a Product. Each milestone payment by Gilead to JT hereunder shall be payable only once, regardless of the number of times achieved with one Product or multiple Products for use with respect to HIV. Each such payment shall be [*] under this Agreement. For clarification, the milestone payments hereunder shall be paid to JT from Gilead and/or its Affiliates from the United States and/or up to two (2) other jurisdictions for which no withholding tax is applicable. Milestone Event for a Product containing Compound Payment Amount
Sample 1
AutoNDA by SimpleDocs
HIV vertical transmission of HIV is now rare in the UK following the widespread implementation of antenatal screening, antiretroviral treatment in pregnancy and avoidance of breastfeeding • the risk of vertical HIV transmission in an untreated woman in pregnancy is around 25%. However, with early diagnosis, effective treatment and subsequent viral suppression, the risk of transmission is now very low (under 0.5%) Hepatitis B: • babies born to mothers with hepatitis B are at higher chance of acquiring HBV infection, particularly if the mother has a high level of HBV DNA (viral load)‌ • the risk of transmission depends on the status of the maternal infection • without intervention, 70 to 90% of mothers who have higher infectivity will pass the infection to their baby compared to a 10% risk for mothers who have lower infectivity • perinatal transmission can result in an acute or chronic infection, but babies have a much higher chance of being chronically infected • without vaccination, 95% will have a sub-clinical infection (rather than acute hepatitis) and many become chronic carriers for life • the development of chronic infection after perinatal transmission can be prevented in over 90% of cases by timely vaccination (hepatitis B vaccine +/- hepatitis B immunoglobulin (HBIG)).
Sample 1
HIV. An individual eligible to apply for a HIV payment is a person who -
Sample 1

Related to HIV

  • Licensed Products Lessee will obtain no title to Licensed Products which will at all times remain the property of the owner of the Licensed Products. A license from the owner may be required and it is Lessee's responsibility to obtain any required license before the use of the Licensed Products. Lessee agrees to treat the Licensed Products as confidential information of the owner, to observe all copyright restrictions, and not to reproduce or sell the Licensed Products.

  • Tests and Preclinical and Clinical Trials The studies, tests and preclinical and clinical trials conducted by or, to the Company’s knowledge, on behalf of the Company were and, if still ongoing, are being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all Authorizations and Applicable Laws, including, without limitation, the Federal Food, Drug and Cosmetic Act and the rules and regulations promulgated thereunder (collectively, “FFDCA”); the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the General Disclosure Package and the Prospectus are, to the Company’s knowledge, accurate in all material respects and fairly present the data derived from such studies, tests and trials; except to the extent disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, the Company is not aware of any studies, tests or trials, the results of which the Company believes reasonably call into question the study, test, or trial results described or referred to in the Registration Statement, the General Disclosure Package and the Prospectus when viewed in the context in which such results are described and the clinical state of development; and, except to the extent disclosed in the Registration Statement, the General Disclosure Package or the Prospectus, neither the Company nor any Subsidiary has received any notices or correspondence from the FDA or any Governmental Entity requiring the termination or suspension of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company, other than ordinary course communications with respect to modifications in connection with the design and implementation of such trials, copies of which communications have been made available to you.

  • Product ACCEPTANCE Unless otherwise provided by mutual agreement of the Authorized User and the Contractor, Authorized User(s) shall have thirty (30) days from the date of delivery to accept hardware products and sixty (60) days from the date of delivery to accept all other Product. Where the Contractor is responsible for installation, acceptance shall be from completion of installation. Failure to provide notice of acceptance or rejection or a deficiency statement to the Contractor by the end of the period provided for under this clause constitutes acceptance by the Authorized User(s) as of the expiration of that period. The License Term shall be extended by the time periods allowed for trial use, testing and acceptance unless the Commissioner or Authorized User agrees to accept the Product at completion of trial use. Unless otherwise provided by mutual agreement of the Authorized User and the Contractor, Authorized User shall have the option to run testing on the Product prior to acceptance, such tests and data sets to be specified by User. Where using its own data or tests, Authorized User must have the tests or representative set of data available upon delivery. This demonstration will take the form of a documented installation test, capable of observation by the Authorized User, and shall be made part of the Contractor’s standard documentation. The test data shall remain accessible to the Authorized User after completion of the test. In the event that the documented installation test cannot be completed successfully within the specified acceptance period, and the Contractor or Product is responsible for the delay, Authorized User shall have the option to cancel the order in whole or in part, or to extend the testing period for an additional thirty (30) day increment. Authorized User shall notify Contractor of acceptance upon successful completion of the documented installation test. Such cancellation shall not give rise to any cause of action against the Authorized User for damages, loss of profits, expenses, or other remuneration of any kind. If the Authorized User elects to provide a deficiency statement specifying how the Product fails to meet the specifications within the testing period, Contractor shall have thirty (30) days to correct the deficiency, and the Authorized User shall have an additional sixty (60) days to evaluate the Product as provided herein. If the Product does not meet the specifications at the end of the extended testing period, Authorized User, upon prior written notice to Contractor, may then reject the Product and return all defective Product to Contractor, and Contractor shall refund any monies paid by the Authorized User to Contractor therefor. Costs and liabilities associated with a failure of the Product to perform in accordance with the functionality tests or product specifications during the acceptance period shall be borne fully by Contractor to the extent that said costs or liabilities shall not have been caused by negligent or willful acts or omissions of the Authorized User’s agents or employees. Said costs shall be limited to the amounts set forth in the Limitation of Liability Clause for any liability for costs incurred at the direction or recommendation of Contractor.

  • Licensed Product “Licensed Product” shall mean any article, composition, apparatus, substance, chemical material, method, process or service whose manufacture, use, or sale is covered or claimed by a Valid Claim within the Patent Rights. For clarity, a “Licensed Product” shall not include other product or material that (a) is used in combination with Licensed Product, and (b) does not constitute an article, composition, apparatus, substance, chemical material, method, process or service whose manufacture, use, or sale is covered or claimed by a Valid Claim within the Patent Rights.

  • Clinical Data and Regulatory Compliance The preclinical tests and clinical trials, and other studies (collectively, “studies”) that are described in, or the results of which are referred to in, Registration Statement, the Pricing Disclosure Package or the Prospectus were and, if still pending, are being conducted in all material respects in accordance with applicable laws, rules, regulations and policies of the Food and Drug Administration of the U.S. Department of Health and Human Services (the “FDA”) or any committee thereof or of any other U.S. or foreign government or drug or medical device regulatory agency, or health care facility Institutional Review Board; each description of the results of such studies is accurate and complete in all material respects and fairly presents the data derived from such studies, and the Company and its subsidiaries have no knowledge of any other studies the results of which are materially inconsistent with, or otherwise call into question, the results described or referred to in the Registration Statement, the Pricing Disclosure Package or the Prospectus; for such studies that have been or are being conducted, the Company and its subsidiaries have made all such filings and obtained all such approvals as may be required by foreign government or drug or medical device regulatory agencies, or foreign health care facility Institutional Review Boards; and no investigational new drug application filed by or on behalf of the Company or any of its subsidiaries with the FDA has been terminated or suspended by the FDA, and neither the FDA nor any applicable foreign regulatory agency has commenced, or, to the knowledge of the Company, threatened to initiate, any action to place a clinical hold order on, or otherwise terminate, delay or suspend, any proposed or ongoing studies conducted or proposed to be conducted by or on behalf of the Company or any of its subsidiaries.

  • Product Testing Upon request, Customer shall provide Operator a laboratory report for each Product delivery by Customer or Customer’s supplier. Operator will not be obligated to receive Contaminated Product for throughput across the Berths, nor will Operator be obligated to accept Product that fails to meet the quality specifications set forth in the arrival notice.

  • Clinical Data The descriptions of the results of any studies and tests conducted by or on behalf of, or sponsored by, the Company or its subsidiaries, or in which the Company has participated, that are described in the Disclosure Package and the Prospectus, or the results of which are referred to in the Disclosure Package and the Prospectus do not contain any misstatement of material fact or omit to state a material fact necessary to make such statements not misleading. The Company has no knowledge of any studies or tests not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Disclosure Package or Prospectus.

  • API If the Software offers integration capabilities via an API, your use of the API may be subject to additional costs or Sage specific policies and terms and conditions (which shall prevail in relation to your use of the API). You may not access or use the API in any way that could cause damage to us or the Software, or in contravention of any applicable laws. We reserve the right in our sole discretion, to: (i) update any API from time to time; (ii) place limitations around your use of any API; and (iii) deny you access to any API in the event of misuse by you or to otherwise protect our legitimate interests.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.

Time is Money Join Law Insider Premium to draft better contracts faster.